PTA-News: Dr. Hönle AG: Hönle Group generated adjusted operating profit of €6.9 million in the 2022/2023 financial year
Business news for the stock market
Gilching (pta036/07.12.2023/17:50) - According to preliminary figures, the Hönle Group achieved sales of €106.3 million in the 2022/2023 financial year (previous year: €116.1 million from continuing operations). Sales are therefore above the previously communicated target range of €100 million to €105 million.
The adjusted operating result (adjusted EBIT) amounts to €6.9 million, which is also above the planned €5.5 million to €6.5 million. In the previous year, the company generated an adjusted EBIT of €8.9 million or €12.2 million from continued operations. Taking into account negative one-off effects, which primarily result from the impairment of inventories in the area of air disinfection, the impairment of goodwills and the severance payment to a former board member, preliminary figures show an operating result (EBIT) of -€9.6 million in the 2022/2023 financial year. Originally Hönle had planned an EBIT of -€7 million to -€8 million. The operating result in the previous year was -€10.1 million respectively plus €5.8 million from continuing operations i.e. without the effects of Raesch Quarz (Germany) GmbH.
The new board of directors dealt intensively with all segments and business areas of the Hönle Group. The first few months therefore were characterized by an inventory and analysis of business activities. As part of strategic corporate management, strategy meetings were held then in all of the group's key business units. The Management Board's strategy is aimed at sustainably strong business development and a return to high profitability for the Hönle Group. In order to specifically develop future-oriented areas of application, product management is being established or expanded in the newly defined business units.
The newly defined "Adhesive Systems", "Disinfection" and "Curing" business units are much more focused on customer requirements than the previous "Adhesives", "Glass & Lamps" and "Equipment & Systems" business segments. They represent the basis for increasing sales in the business units and improving the EBIT margins in these units.
Another focus is on expanding the exchange of information at management and expert level and using synergies between the individual entities of the Hönle Group.
Overall, the Management Board expects sales of between €105 million and €115 million and an operating result of between €6 million and €9 million for the Hönle Group in the 2023/2024 financial year. All business segments of the Hönle Group are expected to achieve a positive operating result and a positive operating cash flow overall.
The 2022/2023 annual report will be published on January 30, 2024 and is available at: https://www.hoenle.com/investor-relation/financial-information# reports.
Dr. Hönle AG is a leading provider of industrial UV technology based in Gilching. With 600 employees, the Hönle Group develops innovative solutions for different areas of application. A focus of its business activities is the development and sale of industrial adhesives and casting compounds. Equipment for drying inks and coatings, curing adhesives and plastics, as well as for disinfecting water, air and surfaces and sunlight simulation are also manufactured. In addition, the group of companies produces UV lamps and quartz glass products, among other things for disinfection and drying processes. The Hönle Group supplies technology and global market leaders and is represented by its own companies and partner companies in more than 20 countries.
emitter: Dr. Hönle AG
address: Nicolaus-Otto-Str. 2, 82205 Gilching
contact person: Peter Weinert
phone: +49 8105 2083 173
ISIN(s): DE0005157101 (share)
stock exchanges: regulated market in Frankfurt; free market in Dusseldorf, free market in Hamburg, free market in Hannover, free market in Munich, free market in Stuttgart; open market in Berlin, Tradegate